Given that ACBP signaling promotes a number of obesity-related features (including hepatosteatosis, weight gain, and hyperlipidemia) [9], we asked whether the neutralization of GABAAR—ACBP signaling would be sufficient to ameliorate obesity. The gene discussed is DBI; the disease is hyperlipidemia.